• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TRα1受体的药理学抑制增强了甲状腺素对大鼠体重减轻的作用:对控制体重的潜在治疗意义。

Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight.

作者信息

Pantos C, Mourouzis I, Paizis I, Malliopoulou V, Xinaris Ch, Moraitis P, Cokkinos A D, Cokkinos D V

出版信息

Diabetes Obes Metab. 2007 Jan;9(1):136-8. doi: 10.1111/j.1463-1326.2006.00587.x.

DOI:10.1111/j.1463-1326.2006.00587.x
PMID:17199732
Abstract

It has been previously reported that thyroid hormone receptor alpha1 (TRalpha1) is involved in the regulation of food intake and heart rhythm. Herein, we show that pharmacological inhibition of TRalpha1 by dronedarone, an amiodarone like compound (shown to antagonize thyroid hormone binding to TRalpha1), prevented the thyroid hormone induced increase in food intake and heart rate acceleration in rats. This resulted in a marked reduction in body weight. It is likely that thyroid analogs may prove potential therapeutic agents for controlling body weight.

摘要

先前已有报道称,甲状腺激素受体α1(TRα1)参与食物摄入和心律的调节。在此,我们表明,决奈达隆(一种类似胺碘酮的化合物,已证明可拮抗甲状腺激素与TRα1的结合)对TRα1的药理抑制作用,可防止甲状腺激素诱导的大鼠食物摄入量增加和心率加快。这导致体重显著下降。甲状腺类似物可能被证明是控制体重的潜在治疗药物。

相似文献

1
Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight.TRα1受体的药理学抑制增强了甲状腺素对大鼠体重减轻的作用:对控制体重的潜在治疗意义。
Diabetes Obes Metab. 2007 Jan;9(1):136-8. doi: 10.1111/j.1463-1326.2006.00587.x.
2
Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1.决奈达隆给药可防止体重增加并增强心脏对缺血应激的耐受性:甲状腺激素受体α1可能参与其中。
Thyroid. 2005 Jan;15(1):16-23. doi: 10.1089/thy.2005.15.16.
3
Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"?甲状腺激素受体α1:心脏细胞“变形”的开关?
J Physiol Pharmacol. 2008 Jun;59(2):253-69.
4
Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.抑制甲状腺激素受体 α1 可损害心肌梗死后小鼠的缺血后心脏功能。
Mol Cell Biochem. 2013 Jul;379(1-2):97-105. doi: 10.1007/s11010-013-1631-9. Epub 2013 Mar 27.
5
Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor.急性 T3 治疗通过 TRα1 受体保护心脏免受缺血再灌注损伤。
Mol Cell Biochem. 2011 Jul;353(1-2):235-41. doi: 10.1007/s11010-011-0791-8. Epub 2011 Mar 26.
6
Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence.决奈达隆作为3,5,3'-三碘甲状腺原氨酸与甲状腺激素受体-α1结合的选择性抑制剂:体内外证据
Endocrinology. 2003 Feb;144(2):552-8. doi: 10.1210/en.2002-220604.
7
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components.胺碘酮和决奈达隆对大鼠给药后对不同心脏组织中甲状腺激素依赖性基因表达的影响。
Eur J Endocrinol. 2007 Jun;156(6):695-702. doi: 10.1530/EJE-07-0017.
8
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.新型选择性神经肽Y(1)受体拮抗剂BMS-193885的药理学特性及食欲抑制作用
Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32. doi: 10.1016/j.ejphar.2008.06.032. Epub 2008 Jun 12.
9
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.胺碘酮与决奈达隆在大鼠急性心肌梗死期间的抗心律失常疗效比较
Eur J Pharmacol. 2007 Jun 14;564(1-3):150-7. doi: 10.1016/j.ejphar.2007.02.052. Epub 2007 Mar 7.
10
Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight.GC-1对甲状腺激素信号通路的选择性激活:控制胆固醇和体重的新方法。
Trends Endocrinol Metab. 2004 May-Jun;15(4):154-7. doi: 10.1016/j.tem.2004.03.008.

引用本文的文献

1
Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor.急性 T3 治疗通过 TRα1 受体保护心脏免受缺血再灌注损伤。
Mol Cell Biochem. 2011 Jul;353(1-2):235-41. doi: 10.1007/s11010-011-0791-8. Epub 2011 Mar 26.
2
New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?甲状腺激素在心脏重构中的作用的新见解:是时候重新考虑了吗?
Heart Fail Rev. 2011 Jan;16(1):79-96. doi: 10.1007/s10741-010-9185-3.
3
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.
甲状腺激素β受体激活与阿托伐他汀联合使用时,在兔、犬和猴中具有额外的降胆固醇活性。
Br J Pharmacol. 2009 Feb;156(3):454-65. doi: 10.1111/j.1750-3639.2009.00038.x. Epub 2009 Jan 22.
4
Possible implications of leptin, adiponectin and ghrelin in the regulation of energy homeostasis by thyroid hormone.瘦素、脂联素和胃饥饿素在甲状腺激素调节能量平衡中的潜在影响。
Endocrine. 2007 Aug;32(1):30-2. doi: 10.1007/s12020-007-9002-5. Epub 2007 Sep 29.